Mark Jacobson, MD
Professor of Medicine, Emeritu
Medicine
School of Medicine

His subsequent research was translational, investigating protective immunity against chronic viral infections, in particular cytomegalovirus (CMV), HIV, and human papillomavirus (HPV). He taught medicine residents and medical students and provided clinical care in the Ward 86 HIV clinic at San Francisco General Hospital until March, 2020, when he moved to the Occupational Medicine division to become the infectious diseases consultant for a team of MDs, NPs and RNs who created a system to manage employee COVID-19 health issues for health care personnel working at SF General and affiliated SF Department of Public Health facilities. This included a Occupational Health Service COVID-19 Hotline and Hotline staff standard work guidance for testing/off-return to work decisions, vaccination, and management of COVID-19 vaccine adverse events. Dr. Jacobson initiated a quality improvement program that analyzes data collected by the Hotline to address questions regarding optimal employee management policies. His QI efforts have resulted in 4 medical journal publications to date. He continues to teach Hotline staff and Occupational Medicine residents, consult with Occupational Medicine leadership re policy changes and special issues that arise, and mentor junior faculty conducting observational studies of COVID-19 in health care personnel. Dr. Jacobson is also the author of Sensing Light, a novel published in 2016 about the unfolding of the AIDS epidemic in 1980s San Francisco from the perspective of front-line, treating physicians (see http://markajacobsonauthor.com/).

• Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy.
  AIDS (London, England) 2016 Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA
• Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.
  Journal of acquired immune deficiency syndromes (1999) 2014 Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA
• The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
  PloS one 2013 Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA, A5030 Study Team
• Asymptomatic cryptococcemia in resource-limited settings.
  Current HIV/AIDS reports 2013 Meyer AC, Jacobson M
• Cytomegalovirus viraemia in the modern antiretroviral era(*).
  HIV medicine 2011 Jacobson M, Lurain N, Hunt P
• Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.
  The Journal of infectious diseases 2011 Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG
• Development of cytomegalovirus (CMV) immune recovery uveitis is associated with Th17 cell depletion and poor systemic CMV-specific T cell responses.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010 Hartigan-O'Connor DJ, Jacobson MA, Tan QX, Sinclair E, Studies of Ocular Complications of AIDS Research Group
• Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series.
  AIDS (London, England) 2009 Jagannathan P, Davis E, Jacobson M, Huang L
• Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
  HIV clinical trials 2009 Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA, A5030 Study Team
• Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients.
  PloS one 2009 Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C
• A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
  Vaccine 2009 Jacobson MA, Adler SP, Sinclair E, Black D, Smith A, Chu A, Moss RB, Wloch MK
• Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic.
  Journal of acquired immune deficiency syndromes (1999) 2008 Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA
• Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008 Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, Sinclair E, Studies of Ocular Complications of AIDS Research Group
• Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS?
  PLoS medicine 2007 Jacobson MA
• Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.
  The Journal of infectious diseases 2006 Sinclair E, Tan QX, Sharp M, Girling V, Poon C, Natta MV, Jabs DA, Inokuma M, Maecker HT, Bredt B, Jacobson MA, Studies of Ocular Complications of AIDS Research Group
• Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
  Vaccine 2006 Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP
• Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2006 Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP
• Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS.
  HIV clinical trials 2005 Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F
• Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy.
  Ophthalmology 2005 Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, Kempen JH, Murphy RL, Studies of Ocular Complications of AIDS Research Group
• The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.
  HIV clinical trials 2005 Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ, ACTG 379…
• Editorial comment: failure of HAART to reconstitute CMV-specific protective immunity.
  The AIDS reader 2005 Jacobson MA
• Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
  Journal of clinical immunology 2005 D'Amico R, Yang Y, Mildvan D, Evans SR, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA
• The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
  Clinical pharmacology and therapeutics 2004 Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD
• Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection.
  Journal of immunology (Baltimore, Md. : 1950) 2004 Shacklett BL, Cox CA, Quigley MF, Kreis C, Stollman NH, Jacobson MA, Andersson J, Sandberg JK, Nixon DF
• Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis.
  The Journal of infectious diseases 2004 Jacobson MA, Maecker HT, Orr PL, D'Amico R, Van Natta M, Li XD, Pollard RB, Bredt BM, Adult AIDS Clinical Trials Group and the Studies of Ocular Complications of AIDS Research Group
• Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis.
  Viral immunology 2004 Marshall BC, Jacobson MA, Adler SP, Studies Of Ocular Complications Of AIDS Research Group
• CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals.
  Viral immunology 2004 Sinclair E, Black D, Epling CL, Carvidi A, Josefowicz SZ, Bredt BM, Jacobson MA
• Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
  The Journal of infectious diseases 2003 Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Glesby MJ, National …
• Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection.
  Journal of virology 2003 Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF
• Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy.
  AIDS (London, England) 2003 Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J
• Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function.
  Journal of acquired immune deficiency syndromes (1999) 2002 Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V
• Association of cytomegalovirus (CMV)-specific CD4+ T lymphocyte reactivity and protective immunity against acquired immunodeficiency syndrome-related CMV retinitis.
  The Journal of infectious diseases 2002 Jacobson MA, Bredt BM
• Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
  Antimicrobial agents and chemotherapy 2002 Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL
• Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease.
  The Journal of infectious diseases 2002 Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE, AIDS Clinical Trials Group, Protocol 204/GlaxoWellcome 123-014, International CMV Prophylaxis Study
• A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
  AIDS (London, England) 2002 Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R, AACTG 325 Protocol Team
• Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
  HIV clinical trials 2001 Aberg JA, Wong MK, Flamm R, Notario GF, Jacobson MA
• Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy.
  The Journal of infectious diseases 2001 Jacobson MA, Schrier R, McCune JM, Torriani FJ, Holland GN, O'Donnell JJ, Freeman WR, Bredt BM
• Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS.
  Journal of clinical microbiology 2001 Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA
• A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects.
  AIDS (London, England) 2000 Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC
• Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.
  The Journal of infectious diseases 2000 Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M
• Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000 Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET
• Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations.
  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999 Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG
• Editorial comment: when to discontinue maintenance therapy for OIs in patients on HAART.
  The AIDS reader 1999 Jacobson MA
• Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999 Jacobson MA, Wilson S, Stanley H, Holtzer C, Cherrington J, Safrin S
• Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS.
  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999 Robles R, Lugo D, Gee L, Jacobson MA
• Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy.
  The Journal of infectious diseases 1998 Aberg JA, Yajko DM, Jacobson MA
• Absence of effect of glutamic acid hydrochloride on the bioavailability of oral ganciclovir in AIDS patients with cytomegalovirus disease.
  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998 Gambertoglio J, Kumar P, Dieterich D, Jacobson MA
• Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1.
  Nature medicine 1998 Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune JM
• Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.
  Archives of internal medicine 1998 Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA
• AIDS-related cytomegalovirus retinitis.
  Drugs of today (Barcelona, Spain : 1998) 1998 Jacobson MA
• Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis.
  American journal of ophthalmology 1998 Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP
• A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
  The Journal of infectious diseases 1998 Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA
• Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
  AIDS (London, England) 1998 Jacobson MA, French M
• Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group.
  AIDS (London, England) 1998 Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, Rich WJ, Jacobson MA
• Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997 Jacobson MA
• AIDS-related disseminated histoplasmosis in San Francisco, California.
  The Western journal of medicine 1997 Fredricks DN, Rojanasthien N, Jacobson MA
• Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection.
  Archives of internal medicine 1997 Jacobson MA, Liu RC, Davies D, Cohen PT
• Severe reversible thrombocytopenia caused by recombinant human granulocyte colony-stimulating factor in an AIDS patient receiving chronic ganciclovir therapy.
  AIDS (London, England) 1997 Holtzer CD, Stanley HD, Jacobson MA
• Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
  The New England journal of medicine 1997 Jacobson MA
• Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.
  Lancet (London, England) 1997 Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R
• Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir.
  AIDS (London, England) 1997 Mueller AJ, Jacobson MA, Hurwitz S, Chuang EL, Friedberg DN, Haidt SJ, Heinemann MH, Jabs DA, Kaplan HJ, Freeman WR
• Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells.
  The Journal of infectious diseases 1996 Kohl S, Sigaroudinia M, Charlebois ED, Jacobson MA
• Diagnosis of neurosyphilis in patients infected with human immunodeficiency virus type 1.
  The Journal of infectious diseases 1996 Marra CM, Gary DW, Kuypers J, Jacobson MA
• Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections.
  Advances in experimental medicine and biology 1996 Jacobson MA
• Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection.
  The Journal of infectious diseases 1996 Harb GE, Mandema JW, Delahunty T, Benowitz NB, Coleman R, Sheiner LB, Jacobson MA
• Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials.
  Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996 Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P
• The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.
  AIDS (London, England) 1995 Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC
• Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.
  The Journal of infectious diseases 1995 Spector SA, Busch DF, Follansbee S, Squires K, Lalezari JP, Jacobson MA, Connor JD, Jung D, Shadman A, Mastre B
• Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team.
  American journal of ophthalmology 1995 Holland GN, Levinson RD, Jacobson MA
• Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
  Clinical pharmacology and therapeutics 1995 Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA
• Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease.
  Scandinavian journal of infectious diseases. Supplementum 1995 Jacobson MA
• Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.
  The Journal of infectious diseases 1994 Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D
• Microbiology of community-acquired bacterial pneumonia in persons with and at risk for human immunodeficiency virus type 1 infection. Implications for rational empiric antibiotic therapy.
  Archives of internal medicine 1994 Burack JH, Hahn JA, Saint-Maurice D, Jacobson MA
• Current management of cytomegalovirus disease in patients with AIDS.
  AIDS research and human retroviruses 1994 Jacobson MA
• Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
  Antimicrobial agents and chemotherapy 1994 Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, Squires L, Smiley ML, Blum MR, Feinberg J
• Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
  The Journal of infectious diseases 1994 Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C
• Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.
  Antimicrobial agents and chemotherapy 1994 Jacobson MA, Polsky B, Causey D, Davis R, Tong W, O'Donnell JJ, Kuppermann BD, Heinemann MH, Feinberg J, Lizak P
• Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
  AIDS (London, England) 1994 Jacobson MA, Wulfsohn M, Feinberg JE, Davis R, Power M, Owens S, Causey D, Heath-Chiozzi ME, Murphy RL, Cheung TW
• Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease.
  Journal of acquired immune deficiency syndromes 1994 Stanley HD, Charlebois E, Harb G, Jacobson MA
• Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection.
  The Journal of infectious diseases 1994 Chin DP, Hopewell PC, Yajko DM, Vittinghoff E, Horsburgh CR, Hadley WK, Stone EN, Nassos PS, Ostroff SM, Jacobson MA
• Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.
  The Journal of infectious diseases 1994 Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Abrams D, Rimland D
• A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.
  The Journal of infectious diseases 1993 Jacobson MA, Causey D, Polsky B, Hardy D, Chown M, Davis R, O'Donnell JJ, Kuppermann BD, Heinemann MH, Holland GN
• Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease.
  Journal of acquired immune deficiency syndromes 1993 Harb GE, Alldredge BK, Coleman R, Jacobson MA
• Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions?
  Drug safety 1993 Harb GE, Jacobson MA
• Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection.
  The Journal of infectious diseases 1993 Jacobson MA, Yajko D, Northfelt D, Charlebois E, Gary D, Brosgart C, Sanders CA, Hadley WK
• An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease.
  Journal of acquired immune deficiency syndromes 1993 Dyner TS, Lang W, Geaga J, Golub A, Stites D, Winger E, Galmarini M, Masterson J, Jacobson MA
• Tolerability of combined ganciclovir and didanosine for the treatment of cytomegalovirus disease associated with AIDS.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993 Jacobson MA, Owen W, Campbell J, Brosgart C, Abrams DI
• Valaciclovir (BW256U87): the L-valyl ester of acyclovir.
  Journal of medical virology 1993 Jacobson MA
• Drug hypersensitivity reactions and human immunodeficiency virus disease.
  Journal of acquired immune deficiency syndromes 1992 Bayard PJ, Berger TG, Jacobson MA
• Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
  The Journal of infectious diseases 1992 Reddy MM, Grieco MH, McKinley GF, Causey DM, van der Horst CM, Parenti DM, Hooton TM, Davis RB, Jacobson MA
• Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
  Antimicrobial agents and chemotherapy 1992 Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA
• Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients.
  AIDS (London, England) 1992 Jacobson MA, Stanley HD, Heard SE
• Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
  The American journal of medicine 1992 Jacobson MA
• Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS.
  Lancet (London, England) 1992 Jacobson MA, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Deyton L
• Early predictors of survival in symptomatic HIV-infected persons treated with high-dose zidovudine.
  Journal of acquired immune deficiency syndromes 1992 Bacchetti P, Moss AR, Andrews JC, Jacobson MA
• Review of the toxicities of foscarnet.
  Journal of acquired immune deficiency syndromes 1992 Jacobson MA
• Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499.
  The Journal of infectious diseases 1991 Jacobson MA, Fusaro RE, Galmarini M, Lang W
• Natural history of disseminated Mycobacterium avium complex infection in AIDS.
  The Journal of infectious diseases 1991 Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, Modin GW, Feigal DW, Cusick PS, Sande MA
• Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
  AIDS (London, England) 1991 Harb GE, Bacchetti P, Jacobson MA
• Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection.
  The American review of respiratory disease 1991 Jacobson MA, Mills J, Rush J, Peiperl L, Seru V, Mohanty PK, Hopewell PC, Hadley WK, Broadus VC, Leoung G
• Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
  The Journal of infectious diseases 1991 Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D
• Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
  The Journal of clinical endocrinology and metabolism 1991 Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA
• Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.
  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991 Jacobson MA, Besch CL, Child C, Hafner R, Muth K, Deyton L
• Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
  BMJ (Clinical research ed.) 1991 Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J
• Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
  Journal of acquired immune deficiency syndromes 1991 Jacobson MA, O'Donnell JJ
• Cytomegalovirus esophagitis in patients with AIDS. A clinical, endoscopic, and pathologic correlation.
  Annals of internal medicine 1990 Wilcox CM, Diehl DL, Cello JP, Margaretten W, Jacobson MA
• Campylobacter-like organisms are uncommon pathogens in patients infected with the human immunodeficiency virus.
  Journal of clinical microbiology 1990 Wilcox CM, Byford BA, Forsmark CE, Hadley WK, Cello JP, Jacobson MA
• Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial.
  The New England journal of medicine 1990 Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA
• Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
  Annals of internal medicine 1990 Farese RV, Schambelan M, Hollander H, Stringari S, Jacobson MA
• Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome.
  Transfusion 1990 Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D
• Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
  Journal of chromatography 1990 Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG
• Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study.
  Antimicrobial agents and chemotherapy 1990 Jacobson MA, O'Donnell JJ, Rousell R, Dionian B, Mills J
• Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine.
  The Journal of infectious diseases 1989 Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A
• Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
  Annals of internal medicine 1989 Erlich KS, Jacobson MA, Koehler JE, Follansbee SE, Drennan DP, Gooze L, Safrin S, Mills J
• Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
  Antimicrobial agents and chemotherapy 1989 Jacobson MA, O'Donnell JJ, Mills J
• Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
  Antimicrobial agents and chemotherapy 1989 Aweeka F, Gambertoglio J, Mills J, Jacobson MA
• Cotton-wool spots and cytomegalovirus retinitis in AIDS.
  International ophthalmology clinics 1989 O'Donnell JJ, Jacobson MA
• Cytomegalovirus infection of the laryngeal nerve presenting as hoarseness in patients with acquired immunodeficiency syndrome.
  The American journal of medicine 1989 Small PM, McPhaul LW, Sooy CD, Wofsy CB, Jacobson MA
• Zidovudine-induced fever.
  Journal of acquired immune deficiency syndromes 1989 Jacobson MA, McGrath MS, Joseph P, Molaghan JB, Tadepalli S, Quinn R
• Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
  The Journal of infectious diseases 1988 Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J
• Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis.
  Archives of neurology 1988 Jacobson MA, Mills J, Rush J, O'Donnell JJ, Miller RG, Greco C, Gonzales MF
• Prolonged pancytopenia due to combined ganciclovir and zidovudine therapy.
  The Journal of infectious diseases 1988 Jacobson MA, de Miranda P, Gordon SM, Blum MR, Volberding P, Mills J
• Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex.
  The American journal of medicine 1988 Jacobson MA, Gellermann H, Chambers H
• Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis.
  Journal of medical virology 1988 Jacobson MA, O'Donnell JJ, Brodie HR, Wofsy C, Mills J
• Treatment of cytomegalovirus retinitis in patients with AIDS.
  Reviews of infectious diseases 1988 Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN
• Lymphoma in an HIV-positive man after disappearance of a paraprotein.
  The New England journal of medicine 1988 Ng VL, Jacobson MA, Khayam-Bashi H, McGrath MS
• Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy.
  The Quarterly journal of medicine 1988 Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Feigal D, Mills J
• Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
  Annals of internal medicine 1988 Jacobson MA, Mills J
• Cholestasis and disseminated cytomegalovirus disease in patients with the acquired immunodeficiency syndrome.
  The American journal of medicine 1988 Jacobson MA, Cello JP, Sande MA
• Human pharmacokinetics and tolerance of oral ganciclovir.
  Antimicrobial agents and chemotherapy 1987 Jacobson MA, de Miranda P, Cederberg DM, Burnette T, Cobb E, Brodie HR, Mills J
• Development of cytomegalovirus (CMV) retinitis in a patient with AIDS during ganciclovir therapy for CMV colitis.
  The New England journal of medicine 1987 O'Donnell JJ, Jacobson MA, Mills J